Oliver Sinclair is a dedicated PhD student engaged with the Peter MacCallum Cancer Centre since January 2023 and Cancer Research UK, focusing on innovative CRISPR techniques to identify actionable targets in primary acute myeloid leukemia. Previously, Oliver served as Lab Operations Lead for the UK Lighthouse Lab Network, overseeing a high-capacity COVID diagnostics lab and managing over 80 staff during its transition to a professional workforce. As a Senior Bioscience Lead and Hit Discovery Scientist at AstraZeneca, Oliver employed high-throughput biophysical methods for non-enzymatic drug targets, contributing significant expertise in differential scanning fluorimetry, cellular thermal shift assays, and affinity selection mass spectrometry. Oliver's foundational education includes a Bachelor's degree in Bioprocessing of New Medicines from UCL, completed in 2019.